It happened. The FDA approved Revolution Medicines’ daraxonrasib for second line pancreatic ductal adenocarcinoma under the CNPV program on July 8. The review took under 60 days. The drug is available immediately through specialty pharmacies. After 30 years of trying and failing to drug RAS, after decades of pancreatic cancer patients having essentially nothing beyond chemotherapy, the field has its first targeted therapy for a cancer that kills more than 30,000 Americans every year and has a five year survival rate below 15%.
This is not an incremental advance. Daraxonrasib doubled overall survival in second line pancreatic cancer: 13.2 months versus 6.7 months (HR 0.40, p<0.0001). It doubled progression free survival: 7.2 months versus 3.6 months (HR 0.49, p<0.0001). The data were published simultaneously in The New England Journal of Medicine at ASCO. The FDA granted expanded access before approval. And now it is real.
Revolution CEO Mark Goldsmith said the approval “has the potential to make a meaningful difference for the more than 30,000 Americans who are diagnosed with pancreatic cancer annually.” That is the understatement of the year. Pancreatic cancer is the third leading cause of cancer death in the United States, and until today it had no approved targeted therapy. None. Every other major solid tumor—lung, breast, colorectal, melanoma, prostate—has had targeted drugs for years or decades. Pancreatic cancer had chemotherapy and hope. Now it has daraxonrasib.
Separately, Novartis won approval for Scemblix as the first new frontline CML mechanism since imatinib in 2001. BioNTech signed a $1 billion ADC deal with a Chinese partner despite the ongoing congressional probe. And the China deadline is eight days away.
The Revolution Approval: What It Means for Patients, for the Field, and for the Company
For Patients
This is what matters most. A patient diagnosed with metastatic pancreatic cancer today, whose disease has progressed on first line chemotherapy, now has a drug that doubled the time they are alive compared to what was previously available. Thirteen months versus six and a half. That is not a marginal improvement. That is the difference between being present for another holiday season, another birthday, another six months with the people who matter most.
Pancreatic cancer has always been different from other cancers in one devastating way: the gap between diagnosis and death is brutally short. Most patients are diagnosed at an advanced stage because the disease produces few symptoms until it has spread. First line chemotherapy extends life by months. Second line options have historically offered even less. Against that backdrop, a drug that doubles survival in the second line is as close to transformative as oncology gets in this disease.
The drug is available immediately through specialty pharmacies. That matters because pancreatic cancer does not wait. Every week of delay between approval and access is a week some patients do not have.
For the Oncology Field
Daraxonrasib is the first RAS targeted therapy approved for any solid tumor. RAS was labeled undruggable in the 1980s because the protein’s smooth surface lacked the binding pockets that traditional drugs require. Amgen’s Lumakras cracked the G12C mutation in lung cancer in 2021, and Genentech’s divarasib beat it head to head last week. But daraxonrasib goes broader, targeting pan RAS mutations across multiple subtypes in pancreatic cancer, where the mutation landscape is more varied than the single G12C alteration that dominates in lung.
The approval validates the entire RAS targeting thesis. Revolution proved that you can hit RAS, that hitting it matters clinically, and that the benefit is large enough to change treatment guidelines and earn regulatory approval through the fastest review pathway available. Every company working on RAS targeted therapies—and there are now dozens—benefits from the proof of concept that Revolution established.
The CNPV pathway is also validated by this approval. Daraxonrasib is the highest profile drug to receive CNPV review since Foundayo (approved in 50 days for obesity). Under 60 days from filing to approval for a cancer drug is extraordinary. The program, despite its transparency issues (three undisclosed recipients) and its uncertain future under acting leadership, continues to deliver on its core promise: getting important drugs to patients faster.
For Revolution Medicines
Revolution goes from clinical stage biotech to commercial company overnight. The transition is enormous. Clinical stage companies study drugs. Commercial companies sell them. The infrastructure, the culture, the capabilities required to manufacture, distribute, market, and support a launched oncology product are fundamentally different from what it takes to run clinical trials.
Revolution prepared for this. The company has been building a commercial organization, establishing manufacturing partnerships, and securing distribution agreements throughout the first half of 2026. The expanded access program that preceded approval gave the company operational experience in getting the drug to patients. But the scale changes now. Every oncologist treating pancreatic cancer in the United States needs to know about daraxonrasib—what it does, who it is for, how to prescribe it, and what to expect. That is a commercial buildout that will play out over the coming quarters.
The pipeline behind daraxonrasib is what makes Revolution more than a single product company. RM 055, the catalytic RAS inhibitor with a different mechanism, doubled the chemotherapy response rate in pancreatic cancer at BIO International. The daraxonrasib plus chemotherapy combination showed 58% overall response rate in first line pancreatic cancer at AACR. Revolution is not just launching one drug. It is building a multi drug franchise in a disease that had nothing before this year.
Our Pro brief analyzes the commercial launch trajectory, models the first year revenue ramp, and assesses how Revolution’s competitive position evolves as the KRAS landscape expands. [Details below.]
Novartis Scemblix Approved as First New Frontline CML Mechanism Since 2001
What Happened: The FDA approved Novartis’s Scemblix (asciminib) for newly diagnosed chronic phase chronic myeloid leukemia, making it the first new frontline CML treatment mechanism since imatinib was approved in 2001.
Why a New Mechanism After 25 Years Matters
Imatinib was one of the most important cancer drugs ever developed. It transformed CML from a rapidly fatal leukemia into a chronic condition that most patients can manage for decades. The drug was so successful that it spawned an entire class of BCR ABL tyrosine kinase inhibitors—dasatinib, nilotinib, bosutinib, ponatinib—that refined the approach but did not fundamentally change the mechanism. All of them work by binding the same ATP binding site on the BCR ABL protein.
Scemblix is different. It is a STAMP inhibitor (Specifically Targeting the ABL Myristoyl Pocket), which means it binds a completely different site on the BCR ABL protein than every TKI that came before it. That structural difference matters because patients who develop resistance to ATP site binding TKIs—and a meaningful minority do—may still respond to a drug that binds a different pocket on the same target.
Getting a new mechanism into the frontline setting, where the vast majority of newly diagnosed CML patients begin treatment, is a significant label. Scemblix was already approved for patients who had failed prior TKIs. The frontline approval dramatically expands the addressable population. Now every oncologist diagnosing a new CML patient has the option to start with a STAMP inhibitor instead of a traditional TKI. Whether physicians choose Scemblix over the established frontline TKIs will depend on the full data package (efficacy comparisons, side effect profiles, long term outcomes), but the option is now available.
For Novartis, which originally developed imatinib (Gleevec) and has been the dominant CML franchise for 25 years, the Scemblix frontline approval reinforces the company’s position at the top of the disease. Other companies compete in CML, but Novartis has both the original breakthrough (Gleevec) and the next generation mechanism (Scemblix). The franchise refresh could extend Novartis’s CML dominance for another decade.
BioNTech Signs $1B ADC Deal with DualityBio While Congress Investigates
What Happened: BioNTech signed a deal worth up to $1 billion with China’s DualityBio (now Biocytogen) for ADC candidates.
The Probe Is Not Stopping the Deal Flow
Eight days before the House Select Committee deadline requiring Merck, AbbVie, Lilly, Pfizer, and BMS to disclose details about their China clinical trial sites, BioNTech committed up to $1 billion to a Chinese partner for oncology assets. BioNTech is a German company and was not among the five named in the probe, but the deal demonstrates that the global pharmaceutical industry has not paused its China engagement in response to Washington’s investigation.
The BioNTech/DualityBio deal joins AstraZeneca/CSPC (deepened just days after the probe opened), Lilly/Abbisko (14th deal), and the broader $50 billion plus China licensing pipeline we have tracked since January. The industry’s calculation remains unchanged: the clinical data from Chinese biotech are too strong, the pipeline needs too urgent, and the cost advantages too meaningful to walk away. The political friction is a cost to manage, not a reason to stop.
The deal is also notable because it adds another large pharma player to the ADC space. BioNTech, best known for its COVID vaccine partnership with Pfizer, has been building an oncology pipeline that includes ADCs, bispecific antibodies, and mRNA cancer vaccines. The DualityBio partnership adds ADC candidates sourced from a company with established conjugation chemistry capabilities. For BioNTech’s transition from pandemic vaccine company to diversified oncology platform, the deal is a meaningful step.
Otsuka and Lundbeck Split After 25 Years in Psychiatry
What Happened: Japan’s Otsuka and Denmark’s Lundbeck are unwinding their 25 year psychiatry partnership. Otsuka will take full rights to Rexulti and Abilify Maintena.
Why This Matters: The Otsuka/Lundbeck partnership has been one of the longest running and most commercially successful collaborations in CNS drug development. Abilify (aripiprazole) became one of the best selling drugs in pharmaceutical history. Rexulti (brexpiprazole) followed as a successor franchise. Abilify Maintena, the long acting injectable formulation, serves patients requiring sustained antipsychotic coverage.
The split is not acrimonious—it reflects two companies that have grown in different strategic directions over two and a half decades. Otsuka, which has been expanding its neuroscience portfolio independently, wants full control of the franchise it helped build. Lundbeck, which has been focusing its pipeline on neurological disease beyond psychiatry, may view the split as an opportunity to redeploy capital and attention toward its own strategic priorities.
For the psychiatry market, the practical impact is limited—the drugs remain available and will continue to be marketed. The change is organizational rather than clinical. But the dissolution of a partnership that lasted a quarter century is a reminder that even the most successful collaborations eventually reach a point where the partners’ interests diverge.
Strategic Themes
1. Daraxonrasib Is One of the Most Important Cancer Drug Approvals in a Decade
The first targeted therapy for pancreatic cancer. The first pan RAS therapy for any solid tumor. Doubled overall survival. Doubled progression free survival. NEJM published. CNPV approved in under 60 days. Available immediately. The clinical significance, the scientific milestone, and the speed of the regulatory review all rank this approval among the most consequential in recent oncology history. For a disease that had resisted every prior therapeutic approach, daraxonrasib proves that the most stubborn targets in cancer can be drugged and that the most intractable diseases can be treated.
2. Scemblix Joining the CML Frontline After 25 Years of TKIs Shows That Even “Solved” Diseases Get Better Options
CML is often described as a disease that has been solved by imatinib. In a sense it has—most patients live decades with the condition. But “solved” does not mean “optimal.” Patients who develop TKI resistance, who experience intolerable side effects, or who cannot achieve deep molecular response on existing drugs now have a structurally different option in Scemblix. The frontier of oncology is not just about attacking new diseases. It is also about attacking familiar diseases through better mechanisms.
3. The China Deal Flow Has Not Stopped for the Probe, and It Is Not Going to Stop Before July 17
BioNTech committing $1 billion to DualityBio eight days before the congressional deadline is the latest evidence that the industry has separated the political theater from the commercial reality. The five named companies will respond to the committee’s questions by July 17. The responses will be carefully drafted by lawyers. The deals will continue. The clinical data are too strong and the pipeline needs too urgent for political friction to override the commercial imperative. Whether this calculus changes after the midterms or after the Biotech Investment National Security Act advances is a question for later this year. Right now, the deals flow.
4. Revolution Goes from Clinical Stage to Commercial Overnight, and Execution Is Everything
The approval is the milestone. The commercial launch is the challenge. Building a sales force, establishing physician awareness, securing formulary access, managing payer negotiations, scaling manufacturing, and supporting patients through specialty pharmacy distribution are all tasks that Revolution has never performed at commercial scale. The company has prepared extensively, and the expanded access program provided operational experience. But the transition from trial sponsor to drug company is the most demanding organizational challenge any biotech faces. The next two quarters will show whether Revolution built the infrastructure to match the science.
Frequently Asked Questions
Is daraxonrasib approved?
Yes. The FDA approved daraxonrasib on July 8 under the CNPV program for second line metastatic pancreatic ductal adenocarcinoma. Review took under 60 days. The drug is available immediately through specialty pharmacies. It is the first targeted therapy approved for pancreatic cancer and the first pan RAS therapy for any solid tumor.
What was the clinical data?
OS: 13.2 months versus 6.7 months (HR 0.40, p<0.0001). PFS: 7.2 months versus 3.6 months (HR 0.49, p<0.0001). Consistent across the intent to treat population and the RAS G12 subgroup. Published in The New England Journal of Medicine at ASCO.
What is Scemblix?
Novartis’s asciminib, a STAMP inhibitor approved for newly diagnosed frontline CML. It binds a different site on the BCR ABL protein than all existing TKIs. First new frontline CML mechanism since imatinib in 2001.
What is the BioNTech/DualityBio deal?
Up to $1 billion for ADC candidates. BioNTech is German and was not among the five companies named in the House China probe. The deal continues the pattern of China licensing commitments despite the congressional investigation.
When is the China probe deadline?
July 17. Eight days from today. All five named companies (Merck, AbbVie, Lilly, Pfizer, BMS) must respond with details on data protection and oversight at Chinese trial sites.
What happened with Otsuka/Lundbeck?
After 25 years of partnership in psychiatry, the companies are splitting. Otsuka takes full rights to Rexulti and Abilify Maintena. The dissolution reflects diverging strategic priorities rather than conflict.
BioMed Nexus Pro — What Institutional Subscribers Are Reading Today
Revolution Goes Commercial. We model the first year revenue ramp for daraxonrasib, assess the commercial buildout timeline from specialty pharmacy availability to full national oncology penetration, and evaluate how the KRAS competitive landscape (divarasib, RM 055, Kestrel) shapes the franchise trajectory.
CML Gets a New Frontline. We analyze what Scemblix’s STAMP mechanism means for the $5 billion plus CML market, whether it displaces frontline TKIs or sits alongside them, and how Novartis extends its 25 year CML franchise dominance.
China Probe Countdown. We track the eight days to the July 17 deadline, assess what the five named companies’ responses are likely to contain, and evaluate whether BioNTech’s $1 billion DualityBio deal signals that the probe is noise or a genuine inflection point.
Plus: Otsuka/Lundbeck split implications, Revolution pipeline depth (RM 055, first line combination), Section 232 tariff countdown (22 days), and the full H2 catalyst calendar.
About BioMed Nexus
BioMed Nexus delivers institutional grade intelligence to biotech and pharma executives, investors, and clinicians. Our daily briefings and deep dive analyses cut through the noise to deliver the strategic insights that drive better decision making in the life sciences.
Subscribe to receive daily updates and gain access to BioMed Nexus Pro institutional intelligence briefs.
